Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms.

Charles W AbbottSean M BoyleRachel Marty PykeLee D McDanielEric LevyFábio C P NavarroDattatreya MellacheruvuSimo V ZhangMengyao TanRose SantiagoZeid M RusanPamela MilaniGabor BarthaJason HarrisRena McCloryMichael Paul SnyderSekwon JangRichard Chen

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

NEOPS proved the statistically strongest biomarker compared with all single-gene biomarkers, expression signatures, and TMB biomarkers evaluated in this cohort. Subsequent confirmation of these findings in an independent cohort of patients (n = 110) suggests that NEOPS is a robust, novel biomarker of ICB response in melanoma.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
poor prognosis
genome wide
chronic kidney disease
peritoneal dialysis
prognostic factors
copy number
risk factors
dna methylation
genome wide identification